People say, "Oh, Alzheimer's is genetic garbage." That genetic component is only 5%. So that means 95% of Alzheimer's risk is environmental air pollution, microlastics, ultrarocessed food. And a paper just came out showing that sweetener consumption correlates with dementia.And we think we know why. And you've not talked about this publicly yet. No.Let's talk. 73% of the items in the American grocery store are poisoned because sugar is hidden in all the foods. For instance, there's 262 names for sugar and t ...

Almost two decades after David Phillips identifying the unusual form of diabetes in Ethiopia, the disease is finally getting a name https://t.co/d0ojNV4CzH ...

Lilly’s Mounjaro helped kids as young as 10 control their blood sugar and lose weight in a study that may give doctors another tool to fight childhood diabetes https://t.co/PanrgwaVFa ...

Searle has launched a generic version of semaglutide in a tablet form in Pakistan, a country with one of the highest prevalence of diabetes globally https://t.co/vvH3aRYsbX ...

Health Benefits of Fasting - Fasting is presented as a highly effective treatment for high blood pressure, a leading cause of death and disability [1] - Fasting can reduce insulin resistance and enhance cognitive capacities, potentially affecting depression and anxiety [1] - Fasting mobilizes visceral fat, which is linked to heart disease, cancer, and diabetes [2] - Chemical changes that happen with exercise also occur with fasting, such as increasing EDNF, a neurochemical protecting the brain from Alzheimer's disease [3][4] Societal and Lifestyle Context - The report highlights that 76% of people are overweight or obese, indicating a significant public health challenge [3] - The current environment is designed to promote unhealthy lifestyles, making people fat, sick, and miserable [3] Unique Selling Points of Fasting - Fasting is presented as a unique intervention with benefits beyond weight loss [5] - All human beings have the capacity to fast [4] - Water fasting has shown profound effects on conditions unresolved by medications, including polycystic ovarian syndrome [4]

Health Risk Assessment - Neck size may be indicative of heart disease and diabetes risk [1] - The article prompts readers to consider how many inches is too big for neck circumference, implying a threshold exists for increased health risks [1]

Hi. Okay, I can't see anything. That's good.Uh is generally very difficult for me, but I'll try as much as I can. Okay, so um what do I do. I do health.Okay, health is my thing. Okay. So the topic today is how I absolutely love the topic and how all the speakers you've come here.There's a lot of pressure to be able to stand here but almost all the speakers who came here they had entirely different areas that they spoke about but all of it came down to the butterfly butterfly effect or the ripple effect and ...

Core Viewpoint - Eli Lilly has shown significant clinical progress and financial results, positioning itself as the largest healthcare player globally, with a market cap of approximately $684 billion as of August 1, and has the potential to reach a $2 trillion valuation within seven years [1]. Group 1: Weight Management Market - The weight management medicines market is rapidly growing, projected to reach $150 billion in sales by 2035, up from $15 billion last year [2]. - Eli Lilly's weight loss therapy, Zepbound, has proven to be highly effective, outperforming its main competitor, Novo Nordisk's Wegovy, in clinical trials, contributing to substantial revenue growth for the company [3][10]. - Eli Lilly is addressing the limitations of Zepbound, such as its weekly injection requirement, by developing orforglipron, an oral GLP-1 medicine, which has shown promising weight loss results in diabetes patients [6][5]. Group 2: Pipeline and Product Diversification - Eli Lilly's pipeline includes innovative products like bimagrumab, which can mitigate muscle loss associated with weight loss therapies, showing significant weight reduction in combination with Wegovy [8]. - The company is also developing retatrutide, which mimics the action of three gut hormones, potentially making it more effective than Zepbound if approved [9]. - Beyond weight management, Eli Lilly has a strong portfolio in diabetes, oncology, and immunology, with products like Mounjaro, Verzenio, and Ebglyss, indicating a diversified and robust pipeline [11][12]. Group 3: Valuation and Market Outlook - Eli Lilly's forward price-to-earnings ratio is around 37, which is high compared to the healthcare industry's average of 16.5, but justified by its rapid sales and profit growth, along with a strong pipeline and dividend program [13]. - The company is expected to outperform the market and achieve the necessary growth to reach a $2 trillion valuation by the end of 2032 [13].

Clinical Trial Results & Drug Performance - Eli Lilly's diabetes drug, Mjaro, met the goal of a phase three trial by cutting the risk of heart disease in people with type 2 diabetes [1] - The trial showed Mjaro delivered an 8% lower rate of cardiovascular events than Trulicity and a 16% reduction in death from any cause [2] - Data strengthens the case for insurers, particularly in other parts of the world where the drug is launching [3] - One doctor worries the results aren't good enough to convince insurers in the US and might limit coverage of Mjaro since it wasn't significantly better than Trulicity [4] - Analysts were looking for a greater than 10% reduction in cardiovascular events [5] Market & Investor Reaction - The stock experienced a decline of approximately 4% [4] - There was disappointment as the drug didn't show it was significantly better than Trulicity [5][6] Emerging Trends - Plastic surgeons' business is booming due to "Ozempic face" (loose skin from weight loss) [7]

Lilly’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older medicine Trulicity in a head-to-head study https://t.co/53L2jWfyhk ...